Staging preview: health content pending qualified review

Reconstitution and storage

How to reconstitute Tirzepatide

Approved tirzepatide needs no mixing: Mounjaro and Zepbound come as a ready-to-use solution in pens and vials.1 The research vial holds a freeze-dried solid with no FDA-reviewed mixing or storage directions, and bacteriostatic water is sold separately.234 This page covers label use and storage, then lab handling and math for a dry vial.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

How the prescribed pens and vials are used

This section covers how to use tirzepatide as the labels describe it for the prescribed medicines, Mounjaro and Zepbound. The prescriber sets the dose; see Tirzepatide dosage.

  • Forms: a clear, colorless to slightly yellow solution in single-dose pens, single-dose vials, multi-dose vials or KwikPens.1 In the EU, Mounjaro is given once a week with prefilled pens.5
  • Check first: the label says not to use the solution if particles or discoloration are seen.6
  • Where it goes: under the skin of the abdomen or thigh, or the back of the upper arm when another person gives it.78 The site is rotated with each dose.7 About 80% of a dose given under the skin reaches the blood, and exposure was similar at all three sites.9
  • Vials: patients use a syringe suited to the dose, such as a 1 mL syringe that can measure 0.5 mL or 0.6 mL.10 They use a new syringe and needle for every injection.10
  • Pens: a KwikPen must never be shared, even with a new needle, because of the risk of blood-borne infection.11

General background on under-the-skin injections of prescribed medicines: How subcutaneous injections are given.

Label storage for the approved solution

The Zepbound label gives these storage rules:

  • Refrigerate at 2°C to 8°C (36°F to 46°F).12
  • If needed, single-dose pens and vials can be kept unrefrigerated, at no more than 30°C (86°F), for up to 21 days in total.13
  • Do not freeze, and do not use if frozen. Protect from heat and light in the original carton.14
  • Opened multi-dose vials and KwikPens are thrown away after 30 days at room temperature, 30 days after first use, or 4 weekly doses, even if medicine is left.15

These limits describe the labeled solution. They are not stability data for a freeze-dried research vial.

The research vial: what is and is not known

  • Contents: the supplier describes the contents as a white lyophilized (freeze-dried) solid.2
  • Diluent: bacteriostatic water is not included and is sold separately.4
  • Labeling: the supplier labels its products for research purposes only, not for human consumption.16
  • Directions: research-labeled tirzepatide has no approved FDA application, so there are no FDA-reviewed directions for mixing, measuring or storing it.317
  • Gaps: we found no supplier data on excipients, salt form, exact fill, a recommended diluent volume or stability after mixing, so this page gives no shelf life for a mixed vial.

Lab handling of a freeze-dried vial

These are general steps from peptide makers and from diluent and approved-product labels. None was tested on this vial.

  1. Let a cold vial warm up before opening. Peptides are often hygroscopic, so Bachem advises warming them to room temperature in a desiccator first; absorbed water may lower stability and peptide content.26
  2. Know the diluent. Bacteriostatic Water for Injection holds 0.9% or 1.1% benzyl alcohol as a preservative and comes in a multiple-dose container; Sterile Water for Injection has no preservative and comes only in single-dose containers.2728 Some drugs may be incompatible with benzyl alcohol.27
  3. Work aseptically. The diluent labels call for aseptic technique on every entry into and withdrawal from a container.27
  4. Add the liquid gently. One approved freeze-dried product's label says to aim the diluent at the vial wall to prevent foaming, swirl gently until clear, and not shake, because shaking can cloud the solution.29
  5. Inspect the result for clarity and for unexpected precipitation or discoloration.27
  6. Plan for short storage. Both water labels say to use reconstituted solutions promptly and not store them unless the drug's maker directs otherwise.2728 Peptide makers advise against storing peptides in solution; if it cannot be avoided, they suggest frozen single-use aliquots and no repeated freeze-thaw cycles.3031

Concentration math

Adding a diluent turns the dry peptide into a solution of known strength. The arithmetic is the same for any vial:

Concentration (mg/mL) = peptide in the vial (mg) ÷ diluent added (mL)

The table applies the formula to three example vial contents and three example volumes. It is arithmetic only, not a recommended volume or a dose.

Peptide in vial With 1 mL With 2 mL With 3 mL
5 mg 5 mg/mL 2.5 mg/mL about 1.67 mg/mL
20 mg 20 mg/mL 10 mg/mL about 6.67 mg/mL
30 mg 30 mg/mL 15 mg/mL 10 mg/mL

To find the peptide in a smaller volume, multiply the concentration by that volume: at 10 mg/mL, 0.1 mL holds 1 mg. Two inputs drive the result: the vial's actual content and the volume added. The supplier does not state the actual fill, so the labeled amount is an assumption in this math. Bachem, a peptide maker, notes that peptide powder may be only 70% to 90% peptide, the rest being counter-ions and moisture.26 FDA warns that illegally marketed GLP-1 drugs may contain too little, too much or no active ingredient at all.18 The reconstitution calculator runs the same formula, and the peptide units converter handles syringe markings.

Supplies listed with this vial

The store lists five supplies for lab handling of this vial: bacteriostatic water, 3 mL Luer-Lok syringes, 18G 1-inch needles, insulin syringes and alcohol swabs. General lab technique for a freeze-dried vial is in How to reconstitute a peptide vial, and storage of dry and mixed vials is in How to store peptides.

Regulatory notes on handling

In warning letters to other sellers, FDA treated bacteriostatic water sold alongside a research peptide as evidence that the peptide was meant for injection.19 It also cited one seller's peptide guide and peptide calculator as means to prepare an injectable drug for people.20 FDA has received adverse event reports, some needing hospital care, that may be related to dosing errors when patients measured and self-injected compounded semaglutide.21 It has also received reports that may be related to compounded semaglutide or tirzepatide prescribed above the labeled dose.22 In one letter, FDA said injectable products can pose risks of serious harm to users.23 This page describes lab handling of a research material and the label facts for the approved medicines. It is not instructions for use in people.

Back to the Tirzepatide profile. Related: Tirzepatide side effects and Tirzepatide benefits and uses.

More on Tirzepatide

  • Tirzepatide side effects

    Side effects of Tirzepatide as reported in labels, trials and published studies, with links to the full profile. Reviewed by a qualified reviewer.

  • Tirzepatide dosage

    Published dosing information for Tirzepatide from labels and studies, with its source, and why it is not advice for you.

  • Tirzepatide benefits and uses

    What published sources report about Tirzepatide and its uses, with the evidence level of each finding. No promises.

Tirzepatide in the store

Tirzepatide for sale: strengths, stock and shipping are on the product page.

For research use only. Not for human or veterinary use. Read the research use policy.

Frequently asked questions

Where in the thigh to inject tirzepatide?

For the prescribed medicines, the labels list the thigh, the abdomen, or the back of the upper arm when someone else gives the injection, and say to rotate the site with each dose.78 Drug exposure was similar at all three sites.9 For a more exact spot on the thigh, the product's Instructions for Use and the prescriber are the sources to follow. None of this applies to research-labeled vials.

How do you use tirzepatide?

As prescribed, Mounjaro and Zepbound are injected under the skin once weekly, at any time of day, with or without meals.2425 The solution is checked for particles or discoloration first, and vial users take a new syringe and needle for each injection.610 The prescriber sets the dose. Research-labeled tirzepatide is labeled not for human consumption and has no FDA-reviewed directions.163

Do you need to reconstitute tirzepatide?

Not the approved medicines. Mounjaro and Zepbound come ready to use as a solution in pens and vials.1 The research vial is different: the supplier describes it as a white freeze-dried solid and sells bacteriostatic water separately, so a lab must add a diluent before use.24 There are no FDA-reviewed directions for that step.3

How long does tirzepatide last after mixing?

For tirzepatide mixed from a research vial, we found no stability data, and there are no FDA-reviewed storage directions, so no shelf life is given here.3 Diluent labels say to use reconstituted solutions promptly and not to store them unless the drug's maker directs otherwise, and peptide makers advise against storing peptides in solution.272830 The approved solution has its own label limits: opened multi-dose vials and KwikPens are discarded after 30 days or 4 weekly doses, and single-dose pens and vials may spend up to 21 days unrefrigerated.1513

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. MOUNJARO Prescribing Information, revised 08/2026: Dosage forms. U.S. Food and Drug Administration (label for Eli Lilly and Company), 2026.
  2. Supplier product specification.
  3. FDA Warning Letter: Gram Peptides, March 31, 2026 (no approved application). U.S. Food and Drug Administration, CDER, 2026.
  4. Same source as 2.
  5. Mounjaro: EPAR (how it is used). European Medicines Agency, 2026.
  6. Same source as 1: Visual inspection.
  7. Same source as 1: Injection sites.
  8. Tirzepatide Injection (drug information): injection sites. MedlinePlus, NIH National Library of Medicine, 2026.
  9. Same source as 1: Absorption.
  10. Same source as 1: Vial administration.
  11. ZEPBOUND Prescribing Information, revised 08/2026: KwikPen sharing. U.S. Food and Drug Administration (label for Eli Lilly and Company), 2026.
  12. Same source as 11: Storage (refrigeration).
  13. Same source as 11: Storage (room temperature).
  14. Same source as 11: Storage (freezing, heat, light).
  15. Same source as 11: Storage (multi-dose vial and KwikPen).
  16. Same source as 2.
  17. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: research-labeled products. U.S. Food and Drug Administration, 2026.
  18. Same source as 17: illegally marketed versions.
  19. Same source as 3: 2026 (bacteriostatic water).
  20. FDA Warning Letter: Royal Peptides LLC, August 24, 2026 (bacteriostatic water and calculator). U.S. Food and Drug Administration, CDER, 2026.
  21. Same source as 17: dosing errors.
  22. Same source as 17: doses above the label.
  23. Same source as 20: 2026 (injectable risk).
  24. Same source as 1: Administration timing.
  25. Same source as 11: Starting dosage.
  26. Care and Handling of Peptides. Bachem, 2021.
  27. Bacteriostatic Water for Injection, USP (multiple-dose vial) prescribing information. Hospira, Inc. (Pfizer labeling), 2019.
  28. Sterile Water for Injection, USP (single-dose vials) prescribing information. Hospira, Inc. (Pfizer labeling), 2026.
  29. ZOMACTON (somatropin) for injection, prescribing information (revised 7/2025). DailyMed, U.S. National Library of Medicine, 2025.
  30. Handling and Storage Guidelines for Peptides (Peptide Guide, chapter 8). Bachem.
  31. Peptide Storage and Handling Guidelines. GenScript.